uniQure (NASDAQ:QURE) CEO Matthew C. Kapusta Sells 3,418 Shares

uniQure (NASDAQ:QURE) CEO Matthew C. Kapusta sold 3,418 shares of the firm’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the transaction, the chief executive officer now owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. This represents a 0.57 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

uniQure Trading Up 109.6 %

NASDAQ QURE traded up $8.00 during mid-day trading on Tuesday, reaching $15.30. 61,665,105 shares of the stock were exchanged, compared to its average volume of 1,618,237. The stock has a market capitalization of $745.72 million, a PE ratio of -1.47 and a beta of 0.89. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. uniQure has a 1-year low of $3.73 and a 1-year high of $17.39. The business’s fifty day simple moving average is $6.20 and its 200 day simple moving average is $6.08.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.12) by $0.21. The business had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. On average, research analysts anticipate that uniQure will post -3.74 earnings per share for the current fiscal year.

Institutional Trading of uniQure

A number of hedge funds have recently added to or reduced their stakes in the business. RTW Investments LP acquired a new position in shares of uniQure during the 3rd quarter valued at about $49,000. China Universal Asset Management Co. Ltd. increased its position in uniQure by 57.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 3,663 shares during the last quarter. Atria Investments Inc purchased a new position in uniQure during the third quarter worth approximately $53,000. Quarry LP acquired a new position in shares of uniQure in the 3rd quarter valued at $58,000. Finally, Vanguard Personalized Indexing Management LLC grew its stake in shares of uniQure by 21.0% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 2,306 shares during the period. 78.83% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of uniQure in a report on Tuesday. Cantor Fitzgerald raised their price objective on shares of uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday. The Goldman Sachs Group cut their price objective on uniQure from $10.00 to $9.00 and set a “neutral” rating for the company in a research report on Wednesday, November 6th. StockNews.com upgraded uniQure to a “sell” rating in a report on Thursday, October 17th. Finally, Royal Bank of Canada cut their price target on uniQure from $16.00 to $14.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $27.33.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.